Compare ALSN & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALSN | ALKS |
|---|---|---|
| Founded | 1915 | 1987 |
| Country | United States | Ireland |
| Employees | 4000 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 8.7B |
| IPO Year | 2011 | 2012 |
| Metric | ALSN | ALKS |
|---|---|---|
| Price | $118.11 | $43.72 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $117.57 | $43.43 |
| AVG Volume (30 Days) | 646.6K | ★ 1.3M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.84% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.49 | N/A |
| Revenue | ★ $3,010,000,000.00 | $1,475,899,000.00 |
| Revenue This Year | $94.98 | $24.26 |
| Revenue Next Year | $5.30 | $4.47 |
| P/E Ratio | $34.32 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $76.01 | $26.99 |
| 52 Week High | $137.62 | $55.67 |
| Indicator | ALSN | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 37.21 | 32.05 |
| Support Level | $110.38 | $36.25 |
| Resistance Level | $118.64 | $51.25 |
| Average True Range (ATR) | 3.65 | 1.39 |
| MACD | -1.53 | -0.10 |
| Stochastic Oscillator | 1.15 | 5.25 |
Allison Transmission is the largest manufacturer of fully automatic transmissions for medium- and heavy-duty commercial vehicles. Its automatic transmissions allow customers to achieve better fuel and operator efficiency than less expensive manual and automated manual transmissions. Allison serves several end markets, including on- and off-highway equipment and military vehicles. Its on-highway business commands approximately 60% global market share. The company's transmissions can be found in Class 4-8 trucks, buses, and a limited number of large passenger vehicles (heavy-duty pickup trucks and motorhomes). Allison also produces commercial hybrid propulsion systems and is developing fully electric powertrains.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.